Shares of Lucira Health (LHDX) - Get Lucira Health Inc. Report jumped Wednesday after the medical device maker said its at-home COVID-19 test would be available for sale on Amazon. (AMZN) - Get Amazon.com Inc. Report
The Lucira Check It test kit provides a PCR-quality test result at home in 30 minutes or less. Test takers can also receive a free verified test result via text on their phone for work or travel.
The kit is "the first at-home COVID-19 self-test to provide an on-the-spot result with molecular accuracy available to millions of U.S. customers on Amazon," Chief Executive Erik Engelson said in a statement.
Lucira shares at last check were up 18% to $6.01.
The Emeryville, Calif., company focuses on developing and commercializing test kits for infectious diseases.
The Check It test kit is available over the counter in the U.S. The test costs $55 on Amazon's site.
Lucira's prescription version was the first prescription molecular diagnostic test for COVID-19 given emergency-use authorization by the U.S. Food and Drug Administration that could be self-administered by consumers at home or used in a doctor's office, the company said.
The 20-minute antibody test, which is made by Nirmidas Biotech of Palo Alto, Calif., was the first U.S.-based test to receive emergency use authorization by the U.S. Food and Drug Administration for point-of-care, the company said in a statement.